Navigation Links
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Date:3/10/2011

PARIS and TARRYTOWN, N.Y., March 10, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).  The data showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel plus placebo (HR=1.01, CI: 0.868 to 1.174).  The addition of aflibercept to docetaxel demonstrated activity as measured by key secondary endpoints of the study: progression free survival (PFS) (HR=0.82, CI: 0.716 to 0.937) and an overall objective response rate (ORR) of 23.3% in the aflibercept arm compared to 8.9 percent in the placebo arm.

The treatment emergent adverse events (AEs) on the aflibercept arm with an incidence that was 10 percent greater than the control arm were stomatitis, weight decrease, hypertension, epistaxis and dysphonia. Grade 3 or 4 AEs that occurred at a frequency of at least 5 percent in patients who received aflibercept were fatigue, stomatitis, disease progression, hypertension, febrile neutropenia, dyspnea, neutropenia, and asthenia.  AEs leading to treatment discontinuation occurred in 27.2 percent of patients in the aflibercept arm compared to 14.6 percent in the placebo arm.  The types and frequencies of AEs reported in the aflibercept treatment arm were generally consistent with those reported in previous studies with anti-VEGF agents.  

The companies will conduct a detailed analysis of the efficacy and safety results of the VITAL study.  Full results will be presente
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... May 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... make a presentation regarding the business strategy of the Company at the Noble ... 1:00 p.m. EDT .  The conference will be held at the Hard Rock ... , , ...
... Inteplast Group,s Integrated Bagging Systems (IBS) Unit is ... packaging division from Uniflex Holdings, part of S. Walter Packaging ... and other medical packaging, and is a valued addition to ... name, sales and customer base into the Inteplast fold. , ...
Cached Medicine Technology:Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010 2Inteplast Acquires Medical Packaging Division 2
(Date:4/17/2014)... shocking rates of suicide are highest in areas with ... smallholdings less than one hectare and trying ... that are highly susceptible to global price fluctuations. , ... that point to a crisis in key areas of ... economy during the 90s. Researchers say that policy intervention ...
(Date:4/17/2014)... TORONTO, April 17, 2014 Giving patients adrenaline after they ... not increase their prospects of surviving long-term, according to ... vast number of patients who have a cardiac arrest ... treating cardiac arrest for decades," said Dr. Steve Lin, ... Michael,s. "Yet, despite advances in medical treatment, long-term survival ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... marvel of the embryo. It begins as a glob of ... to become the cells of our lungs, muscles, nerves and ... in a feat of reverse tissue engineering, Stanford University researchers ... embryonic cells to proliferate and transform into all of the ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... accelerate the entry of outstanding junior investigators into ... graduate research degree or clinical residency has announced ... Director,s Early Independence Awards (EIA) is part of ... workforce, particularly through the support of investigators early ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Picky eating ... a much more serious problem that can affect a child,s ... to differentiate between the two, advises Peter Girolami, clinical director ... Institute in Baltimore. A picky eater may reject certain ...
... America (GSA) and New America Media (NAM) have ... Fellows Program , now in its second year. They represent a ... Jones and from Univision Arizona to Korea Daily Atlanta. The ... scheduled for November 18 to 22 in Boston and tap ...
... September 29, 2011, Cleveland: Cleveland Clinic has received a ... Leonard Krieger Chair in Preventive Cardiology. ... hold the chair. Dr. Hazen,s research spans a broad ... the development of cardiovascular disease to identifying non-invasive testing ...
... Reinberg HealthDay Reporter , THURSDAY, Sept. 29 (HealthDay ... particularly the least educated, poorest, youngest and uninsured, a new ... education, more than 28 percent smoke, similar to people with ... the federal poverty level and 24 percent of adults aged ...
... Ph.D., editor of the Journal of the American Chemical ... Barton, Ph.D. and Rakesh Agrawal, Ph.D., are among 12 ... the nation,s highest honors in science and innovation. ... by a passion for innovation, fearlessness even as they explore ...
Cached Medicine News:Health News:NIH program allows junior investigators to bypass traditional post-doc training 2Health News:Does Your Picky Eater Have a 'Feeding Disorder'? 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 3Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 4Health News:1 in 5 American Workers Still Smokes: CDC 2Health News:1 in 5 American Workers Still Smokes: CDC 3Health News:White House honors editor of American Chemical Society journal and 2 ACS members 2
... Handbook on Injectable Drugs is a ... it quick and easy to check ... you enter the selected drugs, clear ... so you can quickly take clinical ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
... DrDrugs®: Drug Guide for ... over 760 Integrated Calculators ... comprehensive, up-to-date and practical ... in drug dosing calculation ...
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
Medicine Products: